Clinical Trial Detail

NCT ID NCT03221426
Title Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Capecitabine + Cisplatin

Capecitabine + Cisplatin + Pembrolizumab

Cisplatin + Fluorouracil + Pembrolizumab

Cisplatin + Fluorouracil

Age Groups: adult senior

No variant requirements are available.